Clinical Trial Update: A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A [Phase 3]

View source ↗

Summary

Phase 3 trial comparing prophylaxis versus on-demand therapy using a new full-length recombinant factor VIII in patients with severe Hemophilia A; results were …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Recombinant Factor VIII (full-length) (Factor VIII recombinant)

Snippet

Sponsor: Bayer | Conditions: Hemophilia A | Phase 3 | Status: COMPLETED | Results posted: 2014-02-11